H.C. Wainwright initiated coverage of Artiva Biotherapeutics (ARTV) with a Buy rating and $20 price target Artiva is a clinical stage biotechnology company developing natural killer cells for ...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company that has captured the attention of investors and analysts alike with its innovative approach to developing ...

Artiva Biotherapeutics’ (NASDAQ:ARTV – Get Free Report) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th.

On Monday, H.C. Wainwright initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and established a price target of $20.00, aligning with the broader analyst consensus of ...

On Monday, H.C. Wainwright initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and established a price target of $20.00, aligning with the broader analyst consensus of "Strong ...

Barclays PLC purchased a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with ...

Here are some before and after pictures of the company's wordmark and logo. Here's a look at how the new wordmark and logo will appear on storefronts. Social media users react to Walmart's logo ...

Walmart is refreshing its logo for the first time in nearly two decades, highlighting its evolution while also serving as a nod to its past, the big-box retailer announced Monday. The word mark on ...

Analyst Price Forecast Suggests 103.71% Upside As of December 23, 2024, the average one-year price target for Artiva Biotherapeutics is $21.68/share. The forecasts range from a low of $18.18 to a ...

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch Artiva Biotherapeutics raised $167 million in its July IPO to advance ...

Members of the Artiva management team will also be av SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission ...